Sterling Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Sterling Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2K	Sell	2,274 -1,347	-37%	-$5.82K	﹤0.01%	2045
2026 Q1	$10.2K	Sell	3,621 -2,679	-43%	-$9.08K	﹤0.01%	2362
2025 Q4	$20.5K	Sell	6,300 -1,241	-16%	-$4.18K	﹤0.01%	2214
2025 Q3	$21.6K	Buy	7,541 +4,245	+129%	+$10.8K	﹤0.01%	2099
2025 Q2	$7.94K	Buy	3,296 +3,182	+2,791%	+$6.69K	﹤0.01%	2270
2025 Q1	$252	Hold	114	–	–	﹤0.01%	3059
2024 Q4	$621	Hold	114	–	–	﹤0.01%	3011
2024 Q3	$947	Buy	+114	New	+$985	﹤0.01%	2559

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Sterling Capital Management's MRVI Position: Q2 2026 in Review

Sterling Capital Management reduced its Maravai LifeSciences (MRVI) stake by 37% in Q2 2026, selling an estimated $5.82K and leaving 2,274 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Sterling Capital Management first reported a position in MRVI in Q3 2024 and has held it in 8 quarters since. The position peaked at $21.6K in Q3 2025. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Sterling Capital Management held 2,274 shares of Maravai LifeSciences worth $14.2K as of Q2 2026.
Sterling Capital Management sold 1,347 Maravai LifeSciences shares in Q2 2026, an estimated $5.82K.
Maravai LifeSciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2045 holding.
Sterling Capital Management first reported a position in Maravai LifeSciences in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Maravai LifeSciences position peaked at $21.6K in Q3 2025.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.